688739 Stock Overview
A biotechnology company, engages in the research and development, production, and sales of vaccines for human use in China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Liaoning Chengda Biotechnology Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥24.24 |
52 Week High | CN¥35.24 |
52 Week Low | CN¥23.98 |
Beta | 0.63 |
11 Month Change | -11.18% |
3 Month Change | -15.16% |
1 Year Change | -26.46% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -27.05% |
Recent News & Updates
Recent updates
Shareholder Returns
688739 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -4.0% | -3.6% | -2.2% |
1Y | -26.5% | -23.4% | -17.9% |
Return vs Industry: 688739 underperformed the CN Biotechs industry which returned -23.4% over the past year.
Return vs Market: 688739 underperformed the CN Market which returned -17.9% over the past year.
Price Volatility
688739 volatility | |
---|---|
688739 Average Weekly Movement | 3.3% |
Biotechs Industry Average Movement | 6.2% |
Market Average Movement | 6.7% |
10% most volatile stocks in CN Market | 10.1% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688739 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688739's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 1,732 | Yu Mao | www.cdbio.cn |
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use in China. It offers Chengda Suda human rabies and Chengda Libao Human Type B inactivated encephalitis vaccines.
Liaoning Chengda Biotechnology Co.,Ltd. Fundamentals Summary
688739 fundamental statistics | |
---|---|
Market cap | CN¥10.01b |
Earnings (TTM) | CN¥420.34m |
Revenue (TTM) | CN¥1.76b |
23.8x
P/E Ratio5.7x
P/S RatioIs 688739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688739 income statement (TTM) | |
---|---|
Revenue | CN¥1.76b |
Cost of Revenue | CN¥353.23m |
Gross Profit | CN¥1.41b |
Other Expenses | CN¥987.72m |
Earnings | CN¥420.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
Earnings per share (EPS) | 1.02 |
Gross Margin | 79.95% |
Net Profit Margin | 23.87% |
Debt/Equity Ratio | 0% |
How did 688739 perform over the long term?
See historical performance and comparison